This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Galectin Therapeutics’s 8K filing here.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Articles
- Five stocks we like better than Galectin Therapeutics
- Best Stocks Under $5.00
- 3 Travel Stocks That Show the Travel Boom Is Far from Over
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Appaloosa Management Sells These 3 Tech Stocks, Should You?
- The 3 Best Retail Stocks to Shop for in August
- Palo Alto Networks Uptrend Will Continue: AI is Good For Business
